Back to results
US 2017/0157221 A1Published application
Method for treating pervasive development disorders
AssigneeCuremark, LLC
InventorJoan M. Fallon
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCuremark, LLC
InventorJoan M. Fallon
Estimating the term…
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.
A method for treating an individual having an autistic disorder, the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes to promote changes in autistic behavior by ameliorating a symptom of the autistic disorder.
A method for treating an individual having a disorder using digestive enzymes, the disorder comprising ADD (attention deficit disorder) or ADHD (attention deficit hyperactivity disorder), the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes to ameliorate a symptom of the disorder.
A method for treating an individual having a disorder comprising Autism, ADD (attention deficit disorder) or ADHD (attention deficit hyperactivity disorder), the method comprising administering digestive enzymes to the individual to promote protein digestion to improve a symptom of the disorder.
A method for treating an autistic disorder in an individual, who suffers from symptoms of autism and digestive symptoms, the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes.
A method for treating an autistic disorder in an individual who suffers from symptoms of autism and a lack of toilet training, the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes.
A method for treating an autistic disorder in an individual who suffers from symptoms of autism and a gastrointestinal dysfunction, the method comprising administering to the individual two or more doses of an effective amount of digestive enzymes.
A method for determining if an individual exhibiting a symptom of a pervasive developmental disorder (PDD) has improved after the administration of a dose of secretin or digestive enzymes, the method comprising making a quantitative, post-administration measurement of a PDD symptom in the individual, and comparing the post-administration measurement of the PDD symptom to a pre-administration measurement of the PDD symptom, wherein a decrease in one or more symptoms of PDD indicates that the individual has improved.
Dependencies are inferred from the claim text.